Recent Progress in Pharmacogenomics of Antipsychotic Drug Response
- 118 Downloads
Purpose of Review
Pharmacogenomics (PGx) of antipsychotic drug response is an active area of research in the past few years. We reviewed recent PGx studies with an emphasis of development of new methodologies and new research directions.
Traditional candidate gene approach continues to generate evidence to support the associations of antipsychotic response with genes coding for drug targets such as DRD2. Genome-wide association studies have found a few novel genes that may be associated with drug efficacy and adverse events. Recent application of polygenic risk score makes it possible to combine many genetic variants to predict clinical response. Finally, epigenetic research including DNA methylation is emerging and promises new findings that potentially can be applied in clinical practice.
New methodologies may advance PGx closer to clinical application. Multiple genes and epigenomic markers can be used in prediction of clinical phenotypes.
KeywordsPharmacogenomics Antipsychotics Schizophrenia Treatment response Adverse reactions
Compliance with Ethical Standards
Conflict of Interest
Jian-Ping Zhang declares no conflict of interest.
Anil K. Malhotra has received consultancy fees from Genomind, Inc., Concert Pharma, and Biogen. Dr. Malhotra is an advisory board member and receives stock options from InformedDNA.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, et al. A randomized comparison of aripiprazole and Risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull. 2015;41(6):1227–36.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.•• Zhang JP, Lencz T, Zhang RX, et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull. 2016;42(6):1418–37. This is the latest comprehensive review and meta-analysis of genetic basis of antipsychotic drug induced weight gain.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Li Q, Wineinger NE, Fu DJ, et al. Genome-wide association study of paliperidone efficacy. Pharmacogenet Genomics. 2016.Google Scholar
- 30.• Yu H, Wang L, Lv L, et al. Genome-wide association study suggested the PTPRD polymorphisms were associated with weight gain effects of atypical antipsychotic medications. Schizophr Bull. 2016;42(3):814–23. This GWAS found a novel gene that may be associated with antipsychoti-induced weight gain.CrossRefPubMedGoogle Scholar
- 32.Li J, Yoshikawa A, Brennan MD, Ramsey TL, Meltzer HY. Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. Schizophr Res. 2017.Google Scholar
- 38.•• Mas S, Gasso P, Ritter MA, Malagelada C, Bernardo M, Lafuente A. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway. Eur Neuropsychopharmacol. 2015;25(1):51–9. This study applied a novel gene-gene interaction and gene pathway analysis to exmaine antipsychotic induced adverse events.CrossRefPubMedGoogle Scholar
- 46.Santini E, Feyder M, Gangarossa G, Bateup HS, Greengard P, Fisone G. Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism. J Biol Chem. 2012;287(33):27806–12.CrossRefPubMedPubMedCentralGoogle Scholar
- 54.• Frank J, Lang M, Witt SH, Strohmaier J, Rujescu D, Cichon S, et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Mol Psychiatry. 2015;20(2):150–1. This is one of the first studies to use polygeneic risk scores to investigate treatment refractory schizophrenia.CrossRefPubMedGoogle Scholar
- 66.Tang H, Dalton CF, Srisawat U, Zhang ZJ, Reynolds GP. Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia. Int J Neuropsychopharmacol. 2013:1–5.Google Scholar
- 67.Kinoshita M, Numata S, Tajima A, Yamamori H, Yasuda Y, Fujimoto M, et al. Effect of clozapine on DNA methylation in peripheral leukocytes from patients with treatment-resistant schizophrenia. Int J Mol Sci. 2017;18(3)Google Scholar